niacinamide has been researched along with Multiple Myeloma in 17 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors assessed the overall response rate, including confirmed complete response (CR) and partial response, in patients with relapsed/refractory multiple myeloma treated with sorafenib." | 9.19 | A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. ( Barlogie, B; Hoering, A; Hussein, MA; Mazzoni, S; Orlowski, RZ; Popplewell, LL; Sexton, R; Srkalovic, G; Trivedi, H; Zonder, JA, 2014) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 6.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| "Sorafenib is an orally available compound that acts predominantly by targeting the Ras/Raf/MEK/ERK pathway and by inhibiting the vascular endothelial growth factor (VEGF)." | 6.53 | Sorafenib for the treatment of multiple myeloma. ( Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E, 2016) |
| "The inhibitory rate of multiple myeloma cell proliferation was tested by MTT." | 5.40 | [Effects of sorafenib on proliferation and apoptosis of human multiple myeloma cell RPMI 8226]. ( Liu, BL; Liu, X; Qi, MY; Xu, B; Zhou, NC, 2014) |
| "Despite considerable advances, multiple myeloma (MM) remains incurable and the development of novel therapies targeting the interplay between plasma cells (PCs) and their bone marrow (BM) microenvironment remains essential." | 5.39 | Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. ( Catusse, J; Engelhardt, M; Follo, M; Ihorst, G; Schnerch, D; Schüler, J; Udi, J; Waldschmidt, J; Wäsch, R; Wider, D, 2013) |
| "Mcl-1, a survival factor in multiple myeloma, is downregulated at the protein level by sorafenib allowing for the execution of cell death, as ectopic overexpression of this protein protects multiple myeloma cells." | 5.38 | Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. ( Björkholm, M; Celsing, F; De Raeve, H; Fristedt, C; Grandér, D; Gruber, A; Jernberg-Wiklund, H; Johnsson, P; Kharaziha, P; Kokaraki, G; Laane, E; Li, Q; Osterborg, A; Panaretakis, T; Panzar, M; Vanderkerken, K; Zhivotovsky, B, 2012) |
| "The authors assessed the overall response rate, including confirmed complete response (CR) and partial response, in patients with relapsed/refractory multiple myeloma treated with sorafenib." | 5.19 | A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. ( Barlogie, B; Hoering, A; Hussein, MA; Mazzoni, S; Orlowski, RZ; Popplewell, LL; Sexton, R; Srkalovic, G; Trivedi, H; Zonder, JA, 2014) |
| " Ex vivo treatment with 20 µM sorafenib induced apoptosis in around 80 % myeloma cells from six multiple myeloma patients." | 3.81 | Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. ( Anel, A; Azaceta, G; Galán-Malo, P; Jarauta, V; López-Royuela, N; Marzo, I; Naval, J; Palomera, L; Pardo, J; Ramírez-Labrada, A, 2015) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 2.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| "Sorafenib is an orally available compound that acts predominantly by targeting the Ras/Raf/MEK/ERK pathway and by inhibiting the vascular endothelial growth factor (VEGF)." | 2.53 | Sorafenib for the treatment of multiple myeloma. ( Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E, 2016) |
| "The subsequent bone biopsy revealed multiple myeloma." | 1.72 | Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential? ( Engelhardt, M; Jilg, CA; Meyer, PT; Michalski, K; Ruf, J, 2022) |
| "The inhibitory rate of multiple myeloma cell proliferation was tested by MTT." | 1.40 | [Effects of sorafenib on proliferation and apoptosis of human multiple myeloma cell RPMI 8226]. ( Liu, BL; Liu, X; Qi, MY; Xu, B; Zhou, NC, 2014) |
| "Despite considerable advances, multiple myeloma (MM) remains incurable and the development of novel therapies targeting the interplay between plasma cells (PCs) and their bone marrow (BM) microenvironment remains essential." | 1.39 | Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. ( Catusse, J; Engelhardt, M; Follo, M; Ihorst, G; Schnerch, D; Schüler, J; Udi, J; Waldschmidt, J; Wäsch, R; Wider, D, 2013) |
| "Mcl-1, a survival factor in multiple myeloma, is downregulated at the protein level by sorafenib allowing for the execution of cell death, as ectopic overexpression of this protein protects multiple myeloma cells." | 1.38 | Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. ( Björkholm, M; Celsing, F; De Raeve, H; Fristedt, C; Grandér, D; Gruber, A; Jernberg-Wiklund, H; Johnsson, P; Kharaziha, P; Kokaraki, G; Laane, E; Li, Q; Osterborg, A; Panaretakis, T; Panzar, M; Vanderkerken, K; Zhivotovsky, B, 2012) |
| "Sorafenib (Nexavar) is a novel multi-kinase inhibitor that acts predominantly through inhibition of Raf-kinase and VEGF receptor 2, offering the potential for targeting two important aspects of disease biology." | 1.36 | Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. ( Adjei, AA; Haug, JL; Kimlinger, TK; Kumar, S; Rajkumar, SV; Ramakrishnan, V; Timm, M; Wellik, LE; Witzig, TE, 2010) |
| "This study investigated the cytotoxicity and mechanism of action of AS703026, a novel, selective, orally bioavailable MEK1/2 inhibitor, in human multiple myeloma (MM)." | 1.36 | Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. ( Anderson, KC; Burger, P; Chauhan, D; Clark, A; Fulciniti, M; Goutopoulos, A; Hideshima, T; Kim, K; Kong, SY; Li, X; Munshi, NC; Nahar, S; Ogden, J; Podar, K; Rastelli, L; Richardson, P; Rumizen, MJ; Song, W; Tai, YT, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 13 (76.47) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Michalski, K | 1 |
| Jilg, CA | 1 |
| Engelhardt, M | 2 |
| Meyer, PT | 1 |
| Ruf, J | 1 |
| Kennedy, BE | 1 |
| Sadek, M | 1 |
| Elnenaei, MO | 1 |
| Reiman, A | 1 |
| Gujar, SA | 1 |
| Venkateshaiah, SU | 1 |
| Khan, S | 1 |
| Ling, W | 1 |
| Bam, R | 1 |
| Li, X | 2 |
| van Rhee, F | 1 |
| Usmani, S | 1 |
| Barlogie, B | 2 |
| Epstein, J | 1 |
| Yaccoby, S | 1 |
| Yordanova, A | 1 |
| Hose, D | 1 |
| Neben, K | 1 |
| Witzens-Harig, M | 1 |
| Gütgemann, I | 1 |
| Raab, MS | 1 |
| Moehler, T | 1 |
| Goldschmidt, H | 1 |
| Schmidt-Wolf, IG | 1 |
| Srkalovic, G | 1 |
| Hussein, MA | 1 |
| Hoering, A | 1 |
| Zonder, JA | 1 |
| Popplewell, LL | 1 |
| Trivedi, H | 1 |
| Mazzoni, S | 1 |
| Sexton, R | 1 |
| Orlowski, RZ | 1 |
| Ramírez-Labrada, A | 1 |
| López-Royuela, N | 1 |
| Jarauta, V | 1 |
| Galán-Malo, P | 1 |
| Azaceta, G | 1 |
| Palomera, L | 1 |
| Pardo, J | 1 |
| Anel, A | 1 |
| Marzo, I | 1 |
| Naval, J | 1 |
| Zhou, NC | 1 |
| Liu, BL | 1 |
| Qi, MY | 1 |
| Xu, B | 1 |
| Liu, X | 1 |
| Gentile, M | 1 |
| Martino, M | 1 |
| Recchia, AG | 1 |
| Vigna, E | 1 |
| Morabito, L | 1 |
| Morabito, F | 1 |
| Tumber, A | 1 |
| Nuzzi, A | 1 |
| Hookway, ES | 1 |
| Hatch, SB | 1 |
| Velupillai, S | 1 |
| Johansson, C | 1 |
| Kawamura, A | 1 |
| Savitsky, P | 1 |
| Yapp, C | 1 |
| Szykowska, A | 1 |
| Wu, N | 1 |
| Bountra, C | 1 |
| Strain-Damerell, C | 1 |
| Burgess-Brown, NA | 1 |
| Ruda, GF | 1 |
| Fedorov, O | 1 |
| Munro, S | 1 |
| England, KS | 1 |
| Nowak, RP | 1 |
| Schofield, CJ | 1 |
| La Thangue, NB | 1 |
| Pawlyn, C | 1 |
| Davies, F | 1 |
| Morgan, G | 1 |
| Athanasou, N | 1 |
| Müller, S | 1 |
| Oppermann, U | 1 |
| Brennan, PE | 1 |
| Beauparlant, P | 1 |
| Bédard, D | 1 |
| Bernier, C | 1 |
| Chan, H | 1 |
| Gilbert, K | 1 |
| Goulet, D | 1 |
| Gratton, MO | 1 |
| Lavoie, M | 1 |
| Roulston, A | 1 |
| Turcotte, E | 1 |
| Watson, M | 1 |
| Ramakrishnan, V | 1 |
| Timm, M | 1 |
| Haug, JL | 1 |
| Kimlinger, TK | 1 |
| Wellik, LE | 1 |
| Witzig, TE | 1 |
| Rajkumar, SV | 1 |
| Adjei, AA | 1 |
| Kumar, S | 1 |
| Kim, K | 1 |
| Kong, SY | 1 |
| Fulciniti, M | 1 |
| Song, W | 1 |
| Nahar, S | 1 |
| Burger, P | 1 |
| Rumizen, MJ | 1 |
| Podar, K | 2 |
| Chauhan, D | 1 |
| Hideshima, T | 1 |
| Munshi, NC | 1 |
| Richardson, P | 1 |
| Clark, A | 1 |
| Ogden, J | 1 |
| Goutopoulos, A | 1 |
| Rastelli, L | 1 |
| Anderson, KC | 2 |
| Tai, YT | 1 |
| Kharaziha, P | 2 |
| De Raeve, H | 1 |
| Fristedt, C | 1 |
| Li, Q | 1 |
| Gruber, A | 1 |
| Johnsson, P | 1 |
| Kokaraki, G | 1 |
| Panzar, M | 1 |
| Laane, E | 1 |
| Osterborg, A | 1 |
| Zhivotovsky, B | 1 |
| Jernberg-Wiklund, H | 1 |
| Grandér, D | 1 |
| Celsing, F | 1 |
| Björkholm, M | 1 |
| Vanderkerken, K | 1 |
| Panaretakis, T | 2 |
| Ceder, S | 1 |
| Sanchez, C | 1 |
| Udi, J | 1 |
| Schüler, J | 1 |
| Wider, D | 1 |
| Ihorst, G | 1 |
| Catusse, J | 1 |
| Waldschmidt, J | 1 |
| Schnerch, D | 1 |
| Follo, M | 1 |
| Wäsch, R | 1 |
| Burton, A | 1 |
2 reviews available for niacinamide and Multiple Myeloma
| Article | Year |
|---|---|
Sorafenib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Proliferatio | 2016 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; I | 2011 |
2 trials available for niacinamide and Multiple Myeloma
| Article | Year |
|---|---|
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2013 |
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Human | 2014 |
13 other studies available for niacinamide and Multiple Myeloma
| Article | Year |
|---|---|
Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential?
Topics: Aged; Bone Marrow; Gallium Radioisotopes; Humans; Male; Multiple Myeloma; Niacinamide; Oligopeptides | 2022 |
Targeting NAD
Topics: Acrylamides; Adenosine; Adenosine Diphosphate Ribose; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; | 2020 |
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Topics: Acrylamides; Animals; Bone and Bones; Cell Differentiation; Coculture Techniques; Cytokines; Enzyme | 2013 |
Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase Inhibito | 2015 |
[Effects of sorafenib on proliferation and apoptosis of human multiple myeloma cell RPMI 8226].
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Human | 2014 |
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crystallography, X-Ray; | 2017 |
Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Colonic Neo | 2009 |
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Drug Synergism; | 2010 |
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Deat | 2010 |
Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Di | 2012 |
Multitargeted therapies for multiple myeloma.
Topics: Animals; Disease Models, Animal; Humans; Mice; Models, Biological; Molecular Targeted Therapy; Multi | 2013 |
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
Topics: Actins; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2013 |
Speeding up cancer-drug development.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase II as To | 2006 |